Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 2322 • ACR Convergence 2025
Gender-related Differences in Peripheral and Axial Spondyloarthritis
Mehmet Tuncay Duruöz¹, Halise Hande Gezer¹, İlknur Aktaş², Servet Akar³, Nilay Şahin⁴, Özgür Akgül⁵, Sami Hizmetli⁶, Meltem Alkan Melikoğlu⁷, Umut Kalyoncu⁸, Erhan Çapkın⁹, fatma Gülçin Ural¹⁰, Figen Yılmaz¹¹, Sebnem ATAMAN¹² and İlhan Sezer¹³, ¹Marmara University Medical School PMR Department, Rheumatology Division, Istanbul, Turkey, ²Istanbul Fatih Sultan Mehmet Training and Research Hospital, PMR, Turkey, Istanbul, Turkey, ³Department of Medicine, Izmir Katip Çelebi University School of Medicine, Izmir, Turkey, ⁴Balikesir University School of Medicine, PMR, Turkey, Balıkesir, Turkey, ⁵Manisa Celal Bayar University School of Medicine, Rheumatology, Turkey, Manisa, Turkey, ⁶Sivas Cumhuriyet University School of Medine, Rheumatology, Turkey, Sivas, Turkey, ⁷Erzurum Atatürk University School of Medicine, Rheumatology, Turkey, Erzurum, Turkey, ⁸Division of Rheumatology, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey, Ankara, Turkey, ⁹Karadeniz Teknik University School of Medicine, PMR, Turkey, Trabzon, Turkey, ¹⁰Ankara Yildirim Beyazit University School of Medicine, PMR, Turkey, Ankara, Turkey, ¹¹Istanbul Sisli Etfal Training and Research Hospital, PMR, Turkey, Istanbul, Turkey, ¹²Ankara University School of Medicine, Rheumatology, Turkey, Ankara, Turkey, ¹³Akdeniz University School of Medicine, Rheumatology, Turkey, Antalya, Turkey
Background/Purpose: This study sought to compare clinical characteristics between female and male patients with spondyloarthritis (SpA) in a Turkish population.Methods: This study included 489 peripheral…
Abstract Number: 1451 • ACR Convergence 2025
Bimekizumab was Efficacious Regardless of Age, BMI, CRP, or HLA-B27 Status: 1-Year Results from Two Phase 3 Studies
Marina Magrey¹, Helena Marzo-Ortega², Yuho Kadono³, David Nicholls⁴, Martin Rudwaleit⁵, Atul Deodhar⁶, Gaëlle Varkas⁷, Chetan Prajapati⁸, Sarah Kavanagh⁹ and Victoria Navarro-Compan¹⁰, ¹Case Western Reserve University School of Medicine/University Hospitals Cleveland, Richfield, OH, ²NIHR Leeds Biomedical Research Centre, The Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, United Kingdom, ³Department of Orthopaedic Surgery, Saitama Medical University, Saitama, ⁴Clinical Trials Unit, University of the Sunshine Coast, Queensland, Australia, ⁵Bielefeld University, Medical School and University Medical Centre OWL, Klinikum Bielefeld, Department of Rheumatology, Bielefeld, Germany, ⁶Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ⁷Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ⁸UCB, Slough, United Kingdom, ⁹UCB, Morrisville, NC, ¹⁰Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain
Background/Purpose: Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17F in addition to IL-17A, has shown efficacy to Week (Wk) 52 in patients…
Abstract Number: 1407 • ACR Convergence 2025
Trends in Diagnostic Timing and Clinical Features of Axial Spondyloarthritis by Sex and Clinical Subtype: A Multicenter Cohort Over Seven Decades
Carla Saad¹, Rafael Bassara Macedo², Maria Eduarda Veiga¹, Claudia Marques³, Gustavo Resende⁴, Adriana Marinho⁵, Andressa Soares⁶, Cleandro Pires⁷, Débora Rodrigues⁸, Glaucio Castro⁹, Guilherme Bulbol¹⁰, Jamile Carneiro¹¹, José Mauro Fernandes¹², Manuella Ochtrop¹³, Maria Bernadete Gavi¹⁴, Michel Yazbek¹⁵, Nara Cavalcanti¹⁶, Natalia Machado¹⁷, Olivio Malheiro¹⁸, Rejane Vieira¹⁹, Ricardo Lage¹⁸, Rita Menin²⁰, Rywka Golebiovski²¹, Sandra Ribeiro¹⁰, Thauana Oliveira²¹, Tysciana Brito²², Valquiria Diniz¹⁴, Marcelo Pinheiro²³ and Percival Sampaio-Barros²⁴, ¹Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, ²Rheumatology Division, Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo (USP), Sao Paulo, Sao Paulo, Brazil, ³Hospital das Clínicas da Universidade Federal de Pernambuco (UFPE) - PE, Recife, Brazil, ⁴Hospital das Clinicas UFMG, Belo Horizonte, Brazil, ⁵Fundação Hospital do Acre - AC, Rio Branco, Brazil, ⁶Hospital Universitário da Universidade Federal de Santa Catarina (UFSC) - SC, Florianópolis, Brazil, ⁷UNB, Brasilia, Distrito Federal, Brazil, ⁸Fundação Hospital do Acre - AC, Rio Branco, Acre, Brazil, ⁹Hospital Governador Celso Ramos (HCR) - SC, Florianópolis, Santa Catarina, Brazil, ¹⁰Faculdade de Medicina da Universidade Federal do Amazonas (UFAM) - AM, Manaus, Amazonas, Brazil, ¹¹Hospital de Base do Distrito Federal (HBDF) - DF, Brasilia, Distrito Federal, Brazil, ¹²Universidade Federal do Maranhão (UFMA) - MA, São Luiz, Maranhao, Brazil, ¹³Hospital Universitário Pedro Ernesto / UERJ - RJ, Rio de Janeiro, Rio de Janeiro, Brazil, ¹⁴Universidade Federal do Espírito Santo (UFES) - ES, Vitória, Espirito Santo, Brazil, ¹⁵Universidade Estadual de Campinas (UNICAMP) - SP, Campinhas, Sao Paulo, Brazil, ¹⁶Hospital das Clínicas da Universidade Federal de Pernambuco (UFPE) - PE, Recife, Pernambuco, Brazil, ¹⁷Universidade Fedral do Paraná (UFPR) - PR, Curitiba, Parana, Brazil, ¹⁸Hospital das Clínicas da Universidade Federal de Minas Gerais (UFMG) - MG, Belo Horizonte, Minas Gerais, Brazil, ¹⁹Universidade Estadual do Ceará (UECE) - CE, Fortaleza, Ceara, Brazil, ²⁰Faculdade de Medicina de São José do Rio Preto (FAMERP) - SP, São José do Rio Preto, Sao Paulo, Brazil, ²¹Escola Paulista de Medicina (EPM) - Universidade Federal de São Paulo (UNIFESP) - SP, São Paulo, Sao Paulo, Brazil, ²²Faculdade de Medicina da Universidade Federal do Amazonas (UFAM) - AM, Manaus, Brazil, ²³UNIFESP/ EPM, São Paulo, São Paulo, Brazil, ²⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, Brazil
Background/Purpose: Axial Spondyloarthritis (axSpA) frequently eludes early recognition, particularly before structural sacroiliitis becomes visible. We analyzed decade-specific diagnosis delay, clinical subtype distribution, and first-symptom profiles…
Abstract Number: 0541 • ACR Convergence 2025
Inflammatory Back Pain Is Not Associated With HLA-B27 Positivity or CRP Levels in a Nationally Representative U.S. Population
Mark Hwang¹, Seokhun Kim², Charles Green¹, Charles Dillon³, Shervin Assassi⁴, Michael Weisman⁵ and John Reveille⁶, ¹UTHealth Houston, Houston, TX, ²UTHealth Houston, Houston, ³NIH, Bethesda, MD, ⁴Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX, ⁵Cedars-Sinai Medical Center, LOS ANGELES, CA, ⁶Department of Medicine, University of Texas Medical Center, Houston, TX
Background/Purpose: Inflammatory back pain (IBP) is a hallmark symptom of axial spondyloarthritis (axSpA) and is frequently used as a clinical entry point for further evaluation,…
Abstract Number: 2633 • ACR Convergence 2025
Comparative 3-year Safety Outcomes in Patients with Ankylosing Spondylitis Initiating JAK Inhibitor or TNF Inhibitor Therapy
Hsin-Hua Chen, Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China)
Background/Purpose: To compare safety outcomes in patients with ankylosing spondylitis (AS) initiating Janus kinase inhibitors (JAKi) versus tumor necrosis factor inhibitors (TNFi).Methods: This retrospective cohort…
Abstract Number: 2321 • ACR Convergence 2025
Uncovering Clinical Phenotypes of Sexual Dysfunction in Spondyloarthritis: A Multidimensional Analysis
Martín Valdez-López¹, Ana Barrera-Vargas¹, Javier Merayo-Chalico², Irazú Contreras-Yañez³, Carlos Abdiel Abitia Borboa⁴, Iris Paola García-Herrera¹, Raúl Pérez-Gamboa¹ and Guillermo Arturo Guaracha-Basáñez¹, ¹Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Tlalpan, Distrito Federal, Mexico, ²Reumátika, Centro de Vanguardia en Reumatología, Ciudad de México, Federal District, Mexico, ³Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Tlalpan, Mexico, ⁴Universidad Autónoma de Sinaloa Facultad de Medicina Culiacán, Culiacan, Sinaloa, Mexico
Background/Purpose: Spondyloarthritis (SpA) impacts patient’s life, including functionality, QoL, emotional state, and sexual function. The current study was conducted to determine the frequency of sexual…
Abstract Number: 1450 • ACR Convergence 2025
The Novel Digital Therapeutic Axia Improves Disease Activity, Functionality, and Quality of Life in Axial Spondyloarthritis Patients: Results from a Randomized Controlled Trial (Bechterew-App Trial)
Patrick-Pascal Strunz¹, Tobias Heusinger², Maxime Le Maire², Anna Fleischer³, Karsten Sebastian Luetkens⁴, Patricia Possler², Michael Gernert¹, Hannah Labinsky⁵, Robert Leppich⁶, Astrid Schmieder⁷, Ludwig Hammel⁸, Billy Sperlich⁹, Matthias Fröhlich¹ and Marc Schmalzing¹⁰, ¹University Hospital of Wuerzburg, Department of Medicine II, Rheumatology/ Immunology, Wuerzburg, Germany, ²University of Wuerzburg, Wuerzburg, Germany, ³University Hospital of Wuerzburg, Department of Medicine II, Psychosomatics, Wuerzburg, Germany, ⁴University Hospital of Wuerzburg, Institute of Diagnostic and Interventional Radiology, Wuerzburg, Germany, ⁵University Hospital of Wuerzburg, Würzburg, Germany, ⁶University Hospital of Wuerzburg, Chair of Software Engineering (Informatik II), Department of Computer Science, Wuerzburg, Germany, ⁷University Hospital Würzburg, Department of Dermatology, Venereology, and Allergology, Wuerzburg, Germany, ⁸Deutsche Vereinigung Morbus Bechterew e. V., Schweinfurt, Germany, ⁹Integrative and Experimental Exercise Science and Training, Institute for Sports Science, Wuerzburg, Germany, ¹⁰Department of Medicine II, Rheumatology/ Immunology,University Hospital of Wuerzburg, Wuerzburg, Bayern, Germany
Background/Purpose: Axia is a novel digital therapeutic (DTx) specifically designed for patients with axial spondyloarthritis (axSpA), in compliance with the European Medical Device Regulation (MDR).…
Abstract Number: 1332 • ACR Convergence 2025
Mid‐Infrared Spectroscopy for Enhanced Diagnosis of Rheumatic Diseases
Gilad Halpert¹, Yair Dankner², Eri Govrin¹, Abdulla Watad³, Omer Gendelman¹, Shlomo Segev¹, Yehuda Shoenfeld¹ and Howard Amital¹, ¹Sheba Medical Center, Ramat Gan, Israel, ²Shenkar College of Engineering and Design, Ramar Gan, Israel, ³Tel Hashomer Medical Center, Ramat Gan, Israel
Background/Purpose: Spectral analysis of liquid biopsies has recently emerged as a promising, non-invasive approach to improve the diagnosis of various pathologies. Our objective was to…
Abstract Number: 0531 • ACR Convergence 2025
Evaluating the Diagnostic Utility of 14-3-3 eta Autoantibodies in Axial Spondyloarthritis: A Multiplex Assay Approach
Anthony Marotta¹, Walter P. Maksymowych², Stephen Bleakley¹, Stephanie Wichuk³ and Norma Biln⁴, ¹Augurex Life Sciences Corp, Vancouver, BC, Canada, ²Department of Medicine, University of Alberta, ⁵⁶⁸ Heritage Building, Edmonton, AB, Canada, ³University of Alberta, Edmonton, AB, Canada, ⁴Augurex Life Sciences, Vancouver, BC, Canada
Background/Purpose: Novel biomarkers for axSpA are urgently needed to enable earlier diagnosis and improve patient outcomes. An assay for quantifying 14-3-3η autoantibodies (AAbs) has been…
Abstract Number: 2583 • ACR Convergence 2025
CCL20+ monocytes expanded by HLA-B*27 fuel Th17 generation in Axial Spondyloarthritis
Jinyi Zhao¹, Feng Liu², Hui Shi³, Liye Chen¹ and Paul Bowness⁴, ¹Botnar Research Center, University of Oxford, Oxford, United Kingdom, ²University of Oxford, Oxford, United Kingdom, ³Botnar Research Center, University of Oxford, Oxford, England, United Kingdom, ⁴NIHR Oxford Biomedical Research Centre, University of Oxford, NDORMS, Oxford, United Kingdom
Background/Purpose: Axial spondyloarthritis (AxSpA) is a chronic inflammatory arthritis characterized by monocyte activation and Th17 cell expansion. While HLA-B*27 is the strongest genetic risk factor…
Abstract Number: 2315 • ACR Convergence 2025
Alterations in the gut microbiome in ankylosing spondylitis and their correlation with disease activity
Hyemin Jeong¹, Eun-Jung Park² and Chan Hong Jeon¹, ¹Soonchunhyang University Bucheon Hospital, Bucheon, Republic of Korea, ²National Medical Center, Seoul, Republic of Korea
Background/Purpose: The microbiome significantly influences immune dysfunction and gut dysbiosis in patients with ankylosing spondylitis (AS). This study seeks to define the distinct microbial characteristics…
Abstract Number: 1444 • ACR Convergence 2025
Real-world comparative effectiveness of tofacitinib, tumor necrosis factor inhibitors, and interleukin-17 inhibitors among patients with axial spondyloarthritis
Jeffrey Curtis¹, Genevieve Gauthier², Lara Fallon³, David Gruben³, You-Li Ling⁴, Matthew Brouillette³, Arne Yndestad⁵, Yu hong⁶ and Mona Kelkar⁶, ¹Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, ²Pfizer Canada ULC, Kirkland, QC, Canada, Montreal, Canada, ³Pfizer Inc, New York, NY, USA, New York, ⁴Pfizer Inc, New York, NY, USA, New York, NY, ⁵Pfizer Inc, Oslo, Norway, Oslo, Norway, ⁶Genesis Research Group, Hoboken, NJ, USA, New York
Background/Purpose: : In the context of an expanding therapeutic landscape and absence of head-to-head trials in axial spondyloarthritis (axSpA), data on direct comparison of effectiveness…
Abstract Number: 0592 • ACR Convergence 2025
An Interim Analysis of Health-Related Quality of Life Outcomes from an International Multicentre Observational Study in Patients with Axial Spondyloarthritis Initiating Bimekizumab in Real-World Clinical Practice
Xenofon Baraliakos¹, Uta Kiltz¹, Kurt de Vlam², Adeline Ruyssen-Witrand³, Julio Ramírez Garcia⁴, Jessica A. Walsh⁵, Denis Poddubnyy⁶, David Nicholls⁷, Marga Oortgiesen⁸, Francesca Maria Ester Castagna⁹, Marie-Alix Bonny¹⁰, Hervé Besson¹¹, Rajan Bajracharya¹², Patrik Öhagen¹³, Christine de La Loge¹⁰ and William Tillett¹⁴, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ²Department of Rheumatology, UZ Leuven, Leuven, Belgium, ³CHU of Toulouse - Pierre-Paul Riquet Hospital (Inflammation, Infection, Immunology and Locomotor Center - Rheumatology Service, Toulouse, France, ⁴Rheumatology Department, Hospital Clinic and IDIBAPS of Barcelona, Barcelona, Spain, ⁵Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, ⁶Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany, ⁷Clinical Trials Unit, University of the Sunshine Coast, Queensland, Australia, ⁸UCB, Raleigh, NC, ⁹UCB SpA, Milano, Italy, ¹⁰UCB, Brussels, Belgium, ¹¹UCB, Breda, Netherlands, ¹²UCB, Slough, England, United Kingdom, ¹³UCB, Stockholm, Sweden, ¹⁴Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease with a significant burden on patients’ (pts) health-related quality of life (HRQoL).1 Bimekizumab (BKZ), a monoclonal…
Abstract Number: 0526 • ACR Convergence 2025
Identification of Urine Proteomic Biomarkers Associated with Ankylosing Spondylitis
Chang-Nam Son¹, Dong-Ki Jang², So-Hye Nam³, Yoon-Jeong Oh⁴, Sungsin Jo⁵, Jong-Seo Kim⁶ and Tae-Hwan Kim⁷, ¹UIJEONGBU EULJI MEDICAL CENTER, EULJI UNIVERSITY, UIJEONGBU, Republic of Korea, ²School of Biological Sciences, Seoul National University, Seoul, Republic of Korea, ³Division of Rheumatology, Department of Internal Medicine, School of Medicine, Keimyung University, Daegu, Republic of Korea, ⁴Uijeongbu Eulji Medical Center, Eulji University School of Medicine, Uijeongbu, Republic of Korea, ⁵Department of Biology, Soonchunhyang University, Asan,, Republic of Korea, ⁶School of Biological Sciences, Seoul National University, Seoul, ⁷Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea
Background/Purpose: Currently available diagnostic tests for inflammatory arthritis lack sufficient sensitivity and specificity, often requiring the integration of clinical manifestations with physician expertise for accurate…
Abstract Number: 2560 • ACR Convergence 2025
Quality and Accuracy of TikTok Videos on Axial Spondyloarthritis: A Modified DISCERN Analysis
Mahiar Rabie and Susan Harwell, University of Tennessee- Nashville, Nashville, TN
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease of the axial skeleton that can cause significant pain and disability. Its variable and often non-specific…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].